685 related articles for article (PubMed ID: 34358448)
1. The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer.
Freed-Pastor WA; Lambert LJ; Ely ZA; Pattada NB; Bhutkar A; Eng G; Mercer KL; Garcia AP; Lin L; Rideout WM; Hwang WL; Schenkel JM; Jaeger AM; Bronson RT; Westcott PMK; Hether TD; Divakar P; Reeves JW; Deshpande V; Delorey T; Phillips D; Yilmaz OH; Regev A; Jacks T
Cancer Cell; 2021 Oct; 39(10):1342-1360.e14. PubMed ID: 34358448
[TBL] [Abstract][Full Text] [Related]
2. Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer.
Peng H; Li L; Zuo C; Chen MY; Zhang X; Myers NB; Hogg GD; DeNardo DG; Goedegebuure SP; Hawkins WG; Gillanders WE
Front Immunol; 2022; 13():1039226. PubMed ID: 36569934
[TBL] [Abstract][Full Text] [Related]
3. The spatial coexistence of TIGIT/CD155 defines poorer survival and resistance to adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
Ma H; Chen X; Mo S; Mao X; Chen J; Liu Y; Lu Z; Yu S; Chen J
Theranostics; 2023; 13(13):4601-4614. PubMed ID: 37649613
[No Abstract] [Full Text] [Related]
4. TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment.
Kawashima S; Inozume T; Kawazu M; Ueno T; Nagasaki J; Tanji E; Honobe A; Ohnuma T; Kawamura T; Umeda Y; Nakamura Y; Kawasaki T; Kiniwa Y; Yamasaki O; Fukushima S; Ikehara Y; Mano H; Suzuki Y; Nishikawa H; Matsue H; Togashi Y
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795004
[TBL] [Abstract][Full Text] [Related]
5. The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers.
Smazynski J; Hamilton PT; Thornton S; Milne K; Wouters MCA; Webb JR; Nelson BH
Gynecol Oncol; 2020 Jul; 158(1):167-177. PubMed ID: 32446718
[TBL] [Abstract][Full Text] [Related]
6. CD155-TIGIT Axis as a Therapeutic Target for Cancer Immunotherapy.
Mu Y; Guan X
Curr Med Chem; 2024; 31(13):1634-1645. PubMed ID: 38666504
[TBL] [Abstract][Full Text] [Related]
7. Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma.
Wu L; Mao L; Liu JF; Chen L; Yu GT; Yang LL; Wu H; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Cancer Immunol Res; 2019 Oct; 7(10):1700-1713. PubMed ID: 31387897
[TBL] [Abstract][Full Text] [Related]
8. Mutant
Nishi K; Ishikura S; Umebayashi M; Morisaki T; Inozume T; Kinugasa T; Aoki M; Nimura S; Swain A; Yoshida Y; Hasegawa S; Nabeshima K; Sakata T; Shirasawa S; Tsunoda T
Anticancer Res; 2020 Aug; 40(8):4663-4674. PubMed ID: 32727790
[TBL] [Abstract][Full Text] [Related]
9. CD155T/TIGIT Signaling Regulates CD8
He W; Zhang H; Han F; Chen X; Lin R; Wang W; Qiu H; Zhuang Z; Liao Q; Zhang W; Cai Q; Cui Y; Jiang W; Wang H; Ke Z
Cancer Res; 2017 Nov; 77(22):6375-6388. PubMed ID: 28883004
[TBL] [Abstract][Full Text] [Related]
10. Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody Blockade.
Pearce H; Croft W; Nicol SM; Margielewska-Davies S; Powell R; Cornall R; Davis SJ; Marcon F; Pugh MR; Fennell É; Powell-Brett S; Mahon BS; Brown RM; Middleton G; Roberts K; Moss P
Cancer Immunol Res; 2023 Apr; 11(4):435-449. PubMed ID: 36689623
[TBL] [Abstract][Full Text] [Related]
11. Blocking TIGIT/CD155 signalling reverses CD8
Liu L; Wang A; Liu X; Han S; Sun Y; Zhang J; Guo L; Zhang Y
J Transl Med; 2022 Jun; 20(1):280. PubMed ID: 35729552
[TBL] [Abstract][Full Text] [Related]
12. TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells.
Mao L; Xiao Y; Yang QC; Yang SC; Yang LL; Sun ZJ
Oral Oncol; 2021 Oct; 121():105472. PubMed ID: 34333450
[TBL] [Abstract][Full Text] [Related]
13. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
14. Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma.
Burrack AL; Spartz EJ; Raynor JF; Wang I; Olson M; Stromnes IM
Cell Rep; 2019 Aug; 28(8):2140-2155.e6. PubMed ID: 31433988
[TBL] [Abstract][Full Text] [Related]
15. CD155/TIGIT signaling regulates the effector function of tumor-infiltrating CD8+ T cell by NF-κB pathway in colorectal cancer.
Li S; Ding J; Wang Y; Wang X; Lv L
J Gastroenterol Hepatol; 2022 Jan; 37(1):154-163. PubMed ID: 34734434
[TBL] [Abstract][Full Text] [Related]
16. Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis.
Chen C; Guo Q; Fu H; Yu J; Wang L; Sun Y; Zhang J; Duan Y
Biomaterials; 2021 Aug; 275():120988. PubMed ID: 34186238
[TBL] [Abstract][Full Text] [Related]
17. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.
Chauvin JM; Ka M; Pagliano O; Menna C; Ding Q; DeBlasio R; Sanders C; Hou J; Li XY; Ferrone S; Davar D; Kirkwood JM; Johnston RJ; Korman AJ; Smyth MJ; Zarour HM
Clin Cancer Res; 2020 Oct; 26(20):5520-5533. PubMed ID: 32591463
[TBL] [Abstract][Full Text] [Related]
18. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer.
Ge Z; Peppelenbosch MP; Sprengers D; Kwekkeboom J
Front Immunol; 2021; 12():699895. PubMed ID: 34367161
[TBL] [Abstract][Full Text] [Related]
19. Immune Exhaustion of T Cells in Alveolar Echinococcosis Patients and Its Reversal by Blocking Checkpoint Receptor TIGIT in a Murine Model.
Zhang C; Lin R; Li Z; Yang S; Bi X; Wang H; Aini A; Zhang N; Abulizi A; Sun C; Li L; Zhao Z; Qin R; Li X; Li L; Aji T; Shao Y; Vuitton DA; Tian Z; Wen H
Hepatology; 2020 Apr; 71(4):1297-1315. PubMed ID: 31410870
[TBL] [Abstract][Full Text] [Related]
20. CD155/TIGIT, a novel immune checkpoint in human cancers (Review).
Liu L; You X; Han S; Sun Y; Zhang J; Zhang Y
Oncol Rep; 2021 Mar; 45(3):835-845. PubMed ID: 33469677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
